136 related articles for article (PubMed ID: 38502371)
1. Impact of Resistance on Therapeutic Design: A Moran Model of Cancer Growth.
Lacy MS; Jenner AL
Bull Math Biol; 2024 Mar; 86(4):43. PubMed ID: 38502371
[TBL] [Abstract][Full Text] [Related]
2. Evolution of resistance to anti-cancer therapy during general dosing schedules.
Foo J; Michor F
J Theor Biol; 2010 Mar; 263(2):179-88. PubMed ID: 20004211
[TBL] [Abstract][Full Text] [Related]
3. Overview of resistance to systemic therapy in patients with breast cancer.
Gonzalez-Angulo AM; Morales-Vasquez F; Hortobagyi GN
Adv Exp Med Biol; 2007; 608():1-22. PubMed ID: 17993229
[TBL] [Abstract][Full Text] [Related]
4. Adaptive therapy.
Gatenby RA; Silva AS; Gillies RJ; Frieden BR
Cancer Res; 2009 Jun; 69(11):4894-903. PubMed ID: 19487300
[TBL] [Abstract][Full Text] [Related]
5. Leveraging Hypoxia-Activated Prodrugs to Prevent Drug Resistance in Solid Tumors.
Lindsay D; Garvey CM; Mumenthaler SM; Foo J
PLoS Comput Biol; 2016 Aug; 12(8):e1005077. PubMed ID: 27560187
[TBL] [Abstract][Full Text] [Related]
6. A mathematical model of chromosome recombination-induced drug resistance in cancer therapy.
Yang HL; Lei JZ
Math Biosci Eng; 2019 Aug; 16(6):7098-7111. PubMed ID: 31698605
[TBL] [Abstract][Full Text] [Related]
7. Chemotherapy-resistant metastatic breast cancer.
Marquette C; Nabell L
Curr Treat Options Oncol; 2012 Jun; 13(2):263-75. PubMed ID: 22528367
[TBL] [Abstract][Full Text] [Related]
8. Nuclear basic fibroblast growth factor regulates triple-negative breast cancer chemo-resistance.
Li S; Payne S; Wang F; Claus P; Su Z; Groth J; Geradts J; de Ridder G; Alvarez R; Marcom PK; Pizzo SV; Bachelder RE
Breast Cancer Res; 2015 Jul; 17(1):91. PubMed ID: 26141457
[TBL] [Abstract][Full Text] [Related]
9. Tumor-Associated Fibroblasts Promote HER2-Targeted Therapy Resistance through FGFR2 Activation.
Fernández-Nogueira P; Mancino M; Fuster G; López-Plana A; Jauregui P; Almendro V; Enreig E; Menéndez S; Rojo F; Noguera-Castells A; Bill A; Gaither LA; Serrano L; Recalde-Percaz L; Moragas N; Alonso R; Ametller E; Rovira A; Lluch A; Albanell J; Gascon P; Bragado P
Clin Cancer Res; 2020 Mar; 26(6):1432-1448. PubMed ID: 31699826
[TBL] [Abstract][Full Text] [Related]
10. A new challenge for successful immunotherapy by tumors that are resistant to apoptosis: two complementary signals to overcome cross-resistance.
Ng CP; Bonavida B
Adv Cancer Res; 2002; 85():145-74. PubMed ID: 12374285
[TBL] [Abstract][Full Text] [Related]
11. An integrated cellular and sub-cellular model of cancer chemotherapy and therapies that target cell survival.
Cook AB; Ziazadeh DR; Lu J; Jackson TL
Math Biosci Eng; 2015 Dec; 12(6):1219-35. PubMed ID: 26775858
[TBL] [Abstract][Full Text] [Related]
12. Based on whole-exome sequencing to explore the rule of Herceptin and TKI resistance in breast cancer patients.
Guo L; Cheng H; Liu J; Shao W; Luo L; Zheng W; Sun S; Kong D; Chen C
BMC Med Genomics; 2024 Jan; 17(1):25. PubMed ID: 38243282
[TBL] [Abstract][Full Text] [Related]
13. Development of Herceptin resistance in breast cancer cells.
Kute T; Lack CM; Willingham M; Bishwokama B; Williams H; Barrett K; Mitchell T; Vaughn JP
Cytometry A; 2004 Feb; 57(2):86-93. PubMed ID: 14750129
[TBL] [Abstract][Full Text] [Related]
14. Evolving concepts in the systemic drug therapy of breast cancer.
Norton L
Semin Oncol; 1997 Aug; 24(4 Suppl 10):S10-3-S10-10. PubMed ID: 9275000
[TBL] [Abstract][Full Text] [Related]
15. Spatial Heterogeneity and Evolutionary Dynamics Modulate Time to Recurrence in Continuous and Adaptive Cancer Therapies.
Gallaher JA; Enriquez-Navas PM; Luddy KA; Gatenby RA; Anderson ARA
Cancer Res; 2018 Apr; 78(8):2127-2139. PubMed ID: 29382708
[TBL] [Abstract][Full Text] [Related]
16. Differential sensitivities of trastuzumab (Herceptin)-resistant human breast cancer cells to phosphoinositide-3 kinase (PI-3K) and epidermal growth factor receptor (EGFR) kinase inhibitors.
Chan CT; Metz MZ; Kane SE
Breast Cancer Res Treat; 2005 May; 91(2):187-201. PubMed ID: 15868447
[TBL] [Abstract][Full Text] [Related]
17. Chemotherapeutics-induced Oct4 expression contributes to drug resistance and tumor recurrence in bladder cancer.
Lu CS; Shieh GS; Wang CT; Su BH; Su YC; Chen YC; Su WC; Wu P; Yang WH; Shiau AL; Wu CL
Oncotarget; 2017 May; 8(19):30844-30858. PubMed ID: 27244887
[TBL] [Abstract][Full Text] [Related]
18. Modeling the chemotherapy-induced selection of drug-resistant traits during tumor growth.
Cho H; Levy D
J Theor Biol; 2018 Jan; 436():120-134. PubMed ID: 29030212
[TBL] [Abstract][Full Text] [Related]
19. Darpp-32 and its truncated variant t-Darpp have antagonistic effects on breast cancer cell growth and herceptin resistance.
Gu L; Waliany S; Kane SE
PLoS One; 2009 Jul; 4(7):e6220. PubMed ID: 19593441
[TBL] [Abstract][Full Text] [Related]
20. Randomized phase II multicenter trial of two schedules of lapatinib as first- or second-line monotherapy in patients with advanced or metastatic non-small cell lung cancer.
Ross HJ; Blumenschein GR; Aisner J; Damjanov N; Dowlati A; Garst J; Rigas JR; Smylie M; Hassani H; Allen KE; Leopold L; Zaks TZ; Shepherd FA
Clin Cancer Res; 2010 Mar; 16(6):1938-49. PubMed ID: 20215545
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]